• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D-青霉胺:化学性质及其在风湿性疾病中的临床应用

D-penicillamine: chemistry and clinical use in rheumatic disease.

作者信息

Howard-Lock H E, Lock C J, Mewa A, Kean W F

出版信息

Semin Arthritis Rheum. 1986 May;15(4):261-81. doi: 10.1016/0049-0172(86)90022-3.

DOI:10.1016/0049-0172(86)90022-3
PMID:2940684
Abstract

The discovery of D-penicillamine and its uses in medicine are reviewed. Chemical-physical properties are discussed, and the molecular structure of D-penicillamine and several of its reaction products are illustrated. Examples of its three main types of biochemical reactions--sulfhydryl-disulfide exchange, thiazolidine formation, and metal chelation are included. Trials of D-penicillamine in RA patients are reviewed critically. The administration of the drug is discussed in detail, including dosages, clinical and laboratory responses, patterns of adverse side effects or toxicity, drug-induced autoimmune diseases, indications and contraindications, and the monitoring and management of patients.

摘要

本文综述了D-青霉胺的发现及其在医学中的应用。讨论了其化学物理性质,并阐述了D-青霉胺及其几种反应产物的分子结构。文中还列举了其三种主要生化反应的实例——巯基-二硫键交换、噻唑烷形成和金属螯合。对D-青霉胺在类风湿关节炎(RA)患者中的试验进行了严格审查。详细讨论了该药物的给药情况,包括剂量、临床和实验室反应、不良反应或毒性模式、药物诱导的自身免疫性疾病、适应证和禁忌证,以及患者的监测和管理。

相似文献

1
D-penicillamine: chemistry and clinical use in rheumatic disease.D-青霉胺:化学性质及其在风湿性疾病中的临床应用
Semin Arthritis Rheum. 1986 May;15(4):261-81. doi: 10.1016/0049-0172(86)90022-3.
2
[Complications of D-penicillamine treatment of rheumatoid poly-arthritis].青霉胺治疗类风湿性多关节炎的并发症
Therapie. 1976 May-Jun;31(3):385-97.
3
[Side effects of d-penicillamine in the treatment of rheumatoid arthritis].青霉胺治疗类风湿关节炎的副作用
Minerva Med. 1986 May 31;77(22-23):1009-16.
4
Gold vs D-penicillamine double blind study and followup.金制剂与青霉胺双盲研究及随访
J Rheumatol. 1984 Dec;11(6):764-7.
5
Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.类风湿关节炎中D-青霉胺与金制剂对比试验。初步报告。
Ann Rheum Dis. 1974 Nov;33(6):532-5. doi: 10.1136/ard.33.6.532.
6
Penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy.青霉胺在风湿性疾病中的应用:耐受性和疗效的前瞻性研究
J Rheumatol Suppl. 1981 Jan-Feb;7:107-11.
7
[Problems of basic therapy of rheumatic diseases with chloroquine, gold and D-penicillamine].
Internist (Berl). 1979 Sep;20(9):426-32.
8
D-penicillamine.D-青霉胺
Baillieres Clin Rheumatol. 1990 Dec;4(3):553-74. doi: 10.1016/s0950-3579(05)80007-x.
9
Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis.既往金制剂治疗不影响青霉胺治疗类风湿关节炎的不良反应。
Arthritis Rheum. 1982 Aug;25(8):917-22. doi: 10.1002/art.1780250802.
10
Adverse reactions to D-penicillamine after gold toxicity.金中毒后对青霉胺的不良反应。
Br Med J. 1980 Jun 21;280(6230):1498-500. doi: 10.1136/bmj.280.6230.1498.

引用本文的文献

1
Pompholyx-Like Eruptions Induced by Penicillamine in a Patient with Wilson's Disease.青霉胺诱发威尔逊病患者出现类汗疱疹样皮疹
Indian J Dermatol. 2019 Jul-Aug;64(4):321-323. doi: 10.4103/ijd.IJD_328_18.
2
Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.药物重新利用:18种常用药物的体外抗糖化特性
PLoS One. 2018 Jan 4;13(1):e0190509. doi: 10.1371/journal.pone.0190509. eCollection 2018.
3
To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology.阻止希望的破灭:改善病情抗风湿药类别及语义学在现代风湿病学中的地位
Inflammopharmacology. 2017 Apr;25(2):185-190. doi: 10.1007/s10787-017-0320-9. Epub 2017 Feb 13.
4
[Bacterial osteitis. Special considerations in immunocompromised patients].[细菌性骨炎。免疫功能低下患者的特殊考量]
Orthopade. 2004 Mar;33(3):297-304. doi: 10.1007/s00132-003-0594-z.
5
Thyroid function and immune profile in rheumatoid arthritis. A controlled study.类风湿关节炎患者的甲状腺功能与免疫谱:一项对照研究。
Clin Rheumatol. 1996 Nov;15(6):599-603. doi: 10.1007/BF02238551.
6
Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.对患有和未患肾病的类风湿性关节炎患者血清IgA和IgM类风湿因子的测定
Ann Rheum Dis. 1996 Aug;55(8):520-4. doi: 10.1136/ard.55.8.520.
7
Prospects of immunotherapy for rheumatoid arthritis.类风湿关节炎免疫疗法的前景。
Pharm World Sci. 1995 Nov 24;17(6):178-85. doi: 10.1007/BF01870608.
8
Effect of thiol compounds on human complement component C4.硫醇化合物对人补体成分C4的影响。
Biochem J. 1993 Feb 1;289 ( Pt 3)(Pt 3):801-5. doi: 10.1042/bj2890801.
9
Clinical pharmacokinetics of D-penicillamine.D-青霉胺的临床药代动力学
Clin Pharmacokinet. 1987 Nov;13(5):317-33. doi: 10.2165/00003088-198713050-00003.
10
D-penicillamine in the therapy of ankylosing spondylitis.D-青霉胺在强直性脊柱炎治疗中的应用
Clin Rheumatol. 1989 Sep;8(3):419-20. doi: 10.1007/BF02030361.